Skip to content

Vertex Pharmaceuticals Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Thu, Feb 11, 2027, after the market closes · estimates and history

Vertex Pharmaceuticals Inc · E.VRTX.MX · Mexico
Use symbol E.VRTX.MX in our API & Excel add-in to retrieve this data ↓
10,130.00
(+0.00%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 37.96%

Vertex Pharmaceuticals Inc Forecast

Vertex Pharmaceuticals Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 38.0% a year, a typical one-standard-deviation range is 9,588–10,672 over a week, 9,020–11,240 over a month and 6,285–13,975 over a year. (Signals as of 5 Nov 2026.)

Vertex Pharmaceuticals Inc Price Chart

MacroFinance.ai

Vertex Pharmaceuticals Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Vertex Pharmaceuticals Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Vertex Pharmaceuticals Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Vertex Pharmaceuticals Inc
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for Vertex Pharmaceuticals Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on Vertex Pharmaceuticals Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Vertex Pharmaceuticals Inc Trading Strategies

28 backtested tactical asset allocation strategies hold EEM (emerging markets), the closest tradable exposure to Vertex Pharmaceuticals Inc; 2 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

See all 28 strategies holding EEM →

Statistical Distribution of Returns

Plus

How Vertex Pharmaceuticals Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Vertex Pharmaceuticals Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Vertex Pharmaceuticals Inc (Mexico)

Vertex Pharmaceuticals Inc is a listed security in Mexico. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Vertex Pharmaceuticals Inc

Frequently asked questions

What is Vertex Pharmaceuticals Inc?
Vertex Pharmaceuticals Inc is a listed security in Mexico. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Vertex Pharmaceuticals Inc price?
The latest close is 10,130 (5 Nov 2026), +0.00% on the day. The price at the top of the page refreshes during the trading day.
Is Vertex Pharmaceuticals Inc in an uptrend?
As of 5 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Vertex Pharmaceuticals Inc?
20-day realised volatility is 38.0% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 11.0% over a month and 5.3% over a week.
What factors affect Vertex Pharmaceuticals Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Vertex Pharmaceuticals Inc, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Vertex Pharmaceuticals Inc?
28 backtested tactical asset allocation strategies trade Vertex Pharmaceuticals Inc through EEM; 2 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Vertex Pharmaceuticals Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Vertex Pharmaceuticals Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Vertex Pharmaceuticals Inc historical data?
In the Free historical data section of this page: the last 10 years of Vertex Pharmaceuticals Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Vertex Pharmaceuticals Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Vertex Pharmaceuticals Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.VRTX.MX&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-209936
2026-11-199925
2026-11-1810240
2026-11-1710240
2026-11-1310240
2026-11-1210240
2026-11-1110240
2026-11-1010240
2026-11-0910060.6
2026-11-0610060.6
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.